Abstract
Hydroxytyrosol (HT) and its derivatives represent the minor components of Virgin Olive Oil (VOO) that are of great interest for their pharmacological properties and among the most widely researched natural antioxidant compounds. In this review, the occurrence and metabolic fate of HT and its precursors are presented prior to discussing its beneficial effects on health. Bioavailability studies show that the metabolites detected in plasma depend on the model used (animal or human), the HT source (simple molecule or complex precursors) and the dose administered. However, in all cases HT sulphate appears to be the most ubiquitous metabolite in biofluids and it seems probable that it is responsible to a great extent for HT biological effects. Epidemiological evidence of HT and its derivatives against such lifestyle-associated pathologies as cancer, cardiovascular and neurodegenerative diseases is reviewed together with the newest perspectives on the mechanisms of action based on in-vitro and animal studies. According to the reviewed data, HT and its precursors could have the potential clinical use in cardiovascular diseases; more epidemiological data is needed to demonstrate their neurodegenerative diseases and cancer prevention.
Keywords: Cancer, cardiovascular disease, hydroxytyrosol, metabolism, neurodegeneration, signalling pathways.
Current Pharmaceutical Design
Title:Hydroxytyrosol: Emerging Trends in Potential Therapeutic Applications
Volume: 24 Issue: 19
Author(s): Maria Carmen Lopez de las Hazas, Laura Rubio*, Alba Macia and Maria Jose Motilva
Affiliation:
- Food Technology Department, Universitat de Lleida-Agrotecnio Center, Escuela Tecnica Superior de Ingenieria Agraria, Lleida, Alcalde Rovira Roure 191, 25198 Lleida,Spain
Keywords: Cancer, cardiovascular disease, hydroxytyrosol, metabolism, neurodegeneration, signalling pathways.
Abstract: Hydroxytyrosol (HT) and its derivatives represent the minor components of Virgin Olive Oil (VOO) that are of great interest for their pharmacological properties and among the most widely researched natural antioxidant compounds. In this review, the occurrence and metabolic fate of HT and its precursors are presented prior to discussing its beneficial effects on health. Bioavailability studies show that the metabolites detected in plasma depend on the model used (animal or human), the HT source (simple molecule or complex precursors) and the dose administered. However, in all cases HT sulphate appears to be the most ubiquitous metabolite in biofluids and it seems probable that it is responsible to a great extent for HT biological effects. Epidemiological evidence of HT and its derivatives against such lifestyle-associated pathologies as cancer, cardiovascular and neurodegenerative diseases is reviewed together with the newest perspectives on the mechanisms of action based on in-vitro and animal studies. According to the reviewed data, HT and its precursors could have the potential clinical use in cardiovascular diseases; more epidemiological data is needed to demonstrate their neurodegenerative diseases and cancer prevention.
Export Options
About this article
Cite this article as:
de las Hazas Carmen Lopez Maria , Rubio Laura *, Macia Alba and Motilva Jose Maria, Hydroxytyrosol: Emerging Trends in Potential Therapeutic Applications, Current Pharmaceutical Design 2018; 24 (19) . https://dx.doi.org/10.2174/1381612824666180522110314
DOI https://dx.doi.org/10.2174/1381612824666180522110314 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, Member 14 (PARP14)
Mini-Reviews in Medicinal Chemistry Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation
Medicinal Chemistry Mesenchymal Stem Cells and C-type Natriuretic Peptide Signaling: A Proposal for a New Treatment Approach for Skeletal Dysplasias
Current Stem Cell Research & Therapy Pd/C-catalyzed Synthesis of 4-biaryl Substituted 2-amino benzo[h] chromene Derivatives as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Physiological and Pathophysiological Functions of SIRT1
Mini-Reviews in Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic
Anti-Cancer Agents in Medicinal Chemistry Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors
Recent Patents on Biotechnology Maps of cis-Regulatory Nodes in Megabase Long Genome Segments are an Inevitable Intermediate Step Toward Whole Genome Functional Mapping
Current Genomics Commentary Research Highlights: Adaptive PTEN Loss Enhances the Outgrowth of Brain Metastatic Tumour Cells
CNS & Neurological Disorders - Drug Targets Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery